REDX vs. AREC, TRX, ETX, POLB, SAR, C4XD, HEMO, DEST, OBD, and ONC
Should you be buying Redx Pharma stock or one of its competitors? The main competitors of Redx Pharma include Arecor Therapeutics (AREC), Tissue Regenix Group (TRX), e-therapeutics (ETX), Poolbeg Pharma (POLB), Sareum (SAR), C4X Discovery (C4XD), Hemogenyx Pharmaceuticals (HEMO), Destiny Pharma (DEST), Oxford BioDynamics (OBD), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics (LON:AREC) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
Redx Pharma received 153 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
Arecor Therapeutics has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500.
Arecor Therapeutics has higher earnings, but lower revenue than Redx Pharma. Arecor Therapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
Redx Pharma has a net margin of 0.00% compared to Redx Pharma's net margin of -278.81%. Redx Pharma's return on equity of -67.81% beat Arecor Therapeutics' return on equity.
In the previous week, Redx Pharma had 2 more articles in the media than Arecor Therapeutics. MarketBeat recorded 4 mentions for Redx Pharma and 2 mentions for Arecor Therapeutics. Arecor Therapeutics' average media sentiment score of 1.45 beat Redx Pharma's score of 0.24 indicating that Redx Pharma is being referred to more favorably in the news media.
54.2% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Redx Pharma shares are held by institutional investors. 31.3% of Arecor Therapeutics shares are held by company insiders. Comparatively, 18.2% of Redx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Redx Pharma beats Arecor Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Redx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for REDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Redx Pharma Competitors List
Related Companies and Tools
